Company intelligence / Profile preview

TNAX Biopharma Corporation

Ownership: Private
Employees: ~2
Development stage: Preclinical

Overview

TNAX Biopharma is developing novel antibody therapeutics targeting immunoreceptors and their ligands. Their lead candidates include TNAX103 (anti-CD300A mAb) for acute ischemic diseases and TNAX101A/IMB1001 (anti-DNAM-1/CD226 mAb) for immune-mediated inflammatory diseases. TNAX101A has been licensed to IMIDomics for worldwide development and commercialization.

Therapeutic areas: ImmunologyNeurologyGastroenterologyCardiovascularNephrology
Modalities: Monoclonal antibodiesBiological products
Industry: Biotech

Drug pipeline

1 asset

TNAX103

Preclinical

Partnerships

IMIDomics Inc.University of Tsukuba

Beyond the preview

Go deeper on TNAX Biopharma Corporation.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on TNAX Biopharma Corporation.

Explore the full profile